The Naval Medical Logistics Command has a requirement to identify potential sources to provide immunoassay test reagent specific for the lysergic acid diethylamide (LSD) metabolite, 2-oxo-3-hydroxy-LSD. The reagent shall be for the initial (screen) testing for the LSD metabolite 2-oxo-3-hydroxy-LSD in urine from LSD abuse. The reagent must provide performance characteristics of sensitivity and specificity for detection of the LSD metabolite 2-oxo-3-hydroxy-LSD in urine at a desired target concentration of approximately 1.0 ng/ml. The reagent must be compatible for use with the Roche-Hitachi D-P Modular automated drug screening equipment, and must be applicable without modification of the equipment. The reagent must be compatible with the optimal throughput of this system and must not interfere with the optimum performance of other immunoassay procedures in the military laboratories. Be advised that this is not a request for the submission of offers or proposals; no contract award will be made as a result of this notice. Responses should include relative information for a drug screening reagent specific for the LSD metabolite, 2-oxo-3-hydroxy-LSD. Immunoassay kits are medical devices that require FDA approval to market. Responses should indicate FDA compliance or the estimated lead time required to obtain FDA approval for an immunoassay kit specific for the LSD metabolite, 2-oxo-3-hydroxy-LSD. Submit responses no later than Thursday September 2nd to Naval Medical Logistics Command, Code 02 / Ralph Payne, 1681 Nelson Street, Fort Detrick, MD 21702-9203. Responses may also be emailed to [email protected].

Bid Protests Not Available